Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Experimental Neurology|October 25, 2025
The impact of response latency on working memory assessment in miceGrace Jin, Yuyang Leah Liu, Louise Inger, et al.
Journal of Neuroscience Research|October 10, 2023
Understanding the role of the NMDA receptor subunit, GluN2D, in mediating NMDA receptor antagonist-induced behavioral disruptions in male and female miceChitra Vinnakota, Anna Schroeder, Xin Du, et al.
The International Journal of Neuropsychopharmacology|May 7, 2026
Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next DecadeHiroyuki Uchida, Gabriella Gobbi, Joseph Zohar, et al.
Neuroscience and Biobehavioral Reviews|June 11, 2016
Neuregulin-1 and schizophrenia in the genome-wide association study eraMd Shaki Mostaid, David Lloyd, Benny Liberg, et al.
Brain, Behavior, and Immunity|October 23, 2020
Maternal immune activation targeted to a window of parvalbumin interneuron development improves spatial working memory: Implications for autismJay P Nakamura, Brendan Gillespie, Andrew Gibbons, et al.
Psychological Medicine|January 14, 2021
The impact of smoking status on cognition and brain morphology in schizophrenia spectrum disordersElysha Ringin, Vanessa Cropley, Andrew Zalesky, et al.
Schizophrenia Research|March 7, 2012
Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expressionElizabeth Scarr, Suresh Sundram, Azita Deljo, et al.
Molecular Psychiatry|October 31, 2024
Investigating the impact of severe maternal SARS-CoV-2 infection on infant DNA methylation and neurodevelopmentRachel A Hill, Andrew Gibbons, Wittaya Suwakulsiri, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 24, 2021
Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductionsHayley F North, Jason Bruggemann, Vanessa Cropley, et al.
Human Psychopharmacology|March 31, 2009
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trialMichael Berk, Clarissa S Gama, Suresh Sundram, et al.
Pageof 8